Intellia Therapeutics (NASDAQ:NTLA) Trading Down 4.3% - What's Next?

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report)'s share price traded down 4.3% during trading on Friday . The company traded as low as $8.93 and last traded at $9.06. 436,341 shares were traded during trading, a decline of 83% from the average session volume of 2,550,550 shares. The stock had previously closed at $9.46.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Wells Fargo & Company dropped their price objective on Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Wedbush reiterated a "neutral" rating and set a $10.00 price target on shares of Intellia Therapeutics in a report on Monday, May 19th. JPMorgan Chase & Co. reiterated a "neutral" rating and set a $13.00 price target (down from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Wall Street Zen raised shares of Intellia Therapeutics to a "sell" rating in a research note on Monday, March 3rd. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $68.00 target price on shares of Intellia Therapeutics in a research note on Friday, May 9th. Two analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $36.90.

Intellia Therapeutics Trading Up 3.6%

The business's 50-day moving average is $7.99 and its two-hundred day moving average is $10.45. The stock has a market capitalization of $1.00 billion, a PE ratio of -1.78 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.16. The company had revenue of $16.63 million during the quarter, compared to analysts' expectations of $11.39 million. During the same period in the previous year, the company earned ($1.12) EPS. Intellia Therapeutics's quarterly revenue was down 42.6% on a year-over-year basis. On average, analysts predict that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Hedge Funds Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of NTLA. Regeneron Pharmaceuticals Inc. acquired a new stake in Intellia Therapeutics during the 4th quarter valued at $43,177,000. Voloridge Investment Management LLC boosted its position in Intellia Therapeutics by 226.8% in the 4th quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company's stock valued at $17,805,000 after buying an additional 1,059,751 shares during the last quarter. Contrarius Group Holdings Ltd purchased a new position in Intellia Therapeutics in the 4th quarter valued at about $11,798,000. Two Sigma Advisers LP boosted its position in Intellia Therapeutics by 94.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company's stock valued at $23,300,000 after buying an additional 970,700 shares during the last quarter. Finally, Two Sigma Investments LP boosted its position in Intellia Therapeutics by 88.1% in the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company's stock valued at $21,498,000 after buying an additional 863,363 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.